The Neurofibromatosis Association Report of the Board of Trustees Year ended 31 October 2025 Charity Reglstratlon Number 1078790 Scottlsh Charlty Reglstratlon Number SC045051 Company Reglstration Number 03798407 Tha NourofibromatO818 Assoclallon Report and Financial Statements Year Ended 31 October 2025 Charity Name: Charty Regi%tralhM NLffttsr. 10787 Scoltish Charity Ragistrntion N￿knr. SC045051 Company Registration MJMW. 3798407 Charty INoMng N*ne. Ner¥• Tth)YAXS UK Registered office and operational addres¥.' SW20 OLA TekphcTh: E-m811 address.. W8b8lle addr8$8'. 020 8439 1234 knfo@nmtumour8.0ry.uk Norv• Turn¢)ur¥ UK Nerve Tumours UK k• th wo￿n9 nam8 olthe d￿rIty. T*alM its legal nam8'The NeurofibromatoBIs Association.. Board of Tnk*t• Tho eUff•nt Board of Truthi l•.. Richard Gcrf)dè ICh•tr) Mlchael Fry Profe850r Rosalie Femer Jon•lh4n Bru¢è IVKe Chair) Rohan ChanmwJam Proleswr Me•na Up•thyaya Matthew Jones 8•nlor Man•g•m•nt P•r•onn•l The Trustees delegate day-ttrday management of the dwity to.. Kaien Cockbum, Charity DIT￿r Patron• Gillian AndeT% Sinw)n Callow Thomas Ycyjng Prof. D.Gareth Ev Emity (￿n Gwia Baum IndopgndontAudtttXS B#nkws Nat*Jnal V4Èslminstw Bank P S Mathet Flace 1 Park Ro&J Hampton W¢k Kingston. U[￿. ThaTh Surrey lff14AS gjffey I￿l1vx The Nourofibromatosh Amoclallon Roport and Financial Statements Yoar Endod 31 Octobor 2025 Board of Trust￿ Rwrt for tho Yoar End•d 31 October 2025 The Trustees ofThe Neurofibromatosis Asscaation. tr•Jing as Ne￿e Tumours UK {NTUK), are p￿ased lo present Iheir annual rgport and financ￿1 statements the year ended 31 Ociober 2025. The financial statements comply the Chatities Ad 2011, the Companies Act 2006. Trustee Inveslment (ScotlBndl Act 2005, the ch8riti.es Actt￿nts (sco￿8￿1) Regulations 200618$ amended). the lknorandum and Article8 ofA890ciation, and the char￿e$ St*em￿t of R8uMnmended Prathe fchorib•s SORP") (applicable to ¢harib"•s preparin9 their accounts in ￿￿[dance w7th the FirbanCI￿ Reporting Standard app￿Cable in the UK and Rewblbc of Ireland.. FRS 1021 effective from 1 Januwy 2019. ObJoctlvM and Actlvltl•• Nerve Tumour8 UK'S w8ion 8•e8 a firture in *thich the needs of every *￿eSse kntrwledge. ar￿ underglarKlng of NF. and *lll campalgn for change in •reas we beF*ve will imrKoN* the INes of those affected by NF. Conn•ct We a pNotal robe in trirwjiry t￿]ether groy of people interested In NF to maximise SUPF*yI and avail￿￿ to them. Fund We make funds availabk for small woiects lo bodRs and patth groups vknere V+* ￿110¥* il wll make a difference w) temis of avrfweness. uThJerstandin9 & qualty of lrte. The charity wc*ks with the foll¢xing gr￿p$ to xhieve rts mission.. Patients and carers Families WTth NF The medi￿[ wnmunty The NF Specialist Nefv+th of Nurses and Ad¥ws The research communty Iparbujlwly The Nerye TuMoU￿ UK med￿al knisory Boarf) Leadln9 UK Uni¥eNties TuM¢trpS UK The N•urofibromatosls Assoclalion Report and Financlal Statements Y￿r Ended 31 Octobgr 2025 NTUK S￿nS￿ed PHD resear¢r SupporteT8 Volunteers Other¢horth•s and unknella ¢X9ani￿tlon• Overvlew. A¢hlevement• and PerfornMnc• S•rvk• We fund a unique and vital S¢fvi¢e, ¥*hKh Is not provld•d by any other oryanwtion. Our services are parucularfy Important for peo* dlagnosed wth NF. thek lamllles •xl cwern. Many people T*ith NF arn vulnerable and often l$olaled. A la￿lAg 1•go￿ Ll the Coyid Pandem￿ 18 the NF cornm￿￿8 ongoirwJ fear of aft•￿ting h￿p￿81 appointments and large S￿le events, as people are ffK*re susceptibbè lo the Minm du8 to the associated complicats"on8 of NF. Thi8 Impa￿3 on both the that they receNe. and ItK• d)arity'¥ Mmmunlty fuTrJral8*y capabilit￿. There 18 Still a signthcanl backkg of ap￿Intments for gerths and n•urokw dintu. Thi8 was inib.ally caused by reduced NHS 8taffing in 2020 and ￿jbIequént year¥. as many had lJ••n re*loyed to critical and Covld seThic89. but wa¥ made far ￿￿r8e by thg continulng NHS 8tthk¢8 ovor th• t18t cou￿e 01 ye4r8. and thelgngth of tlme It eurrentty tak•* to fill NHS Va￿n￿O¥. The CW ￿ extremty conc6m•d about tho ongoing potèntial impact on mental health both for our benefknarle8 &)d our stsff. due to *rrkload as our Serv￿•5 conbnue lo face increased demand. This increa8ed demand Is due lo both the economK dimate and ts reSu￿ng absence or dfftU￿ in obtaSnlng prfmary and 88condary care ser4kes. Somts 8eMces ar• SYII virtualty or ty td•phon• ¢on$uMatlon vthl¢ C8U8• Smm8ns• problem8 for people vAth NF, vkno elther do not have the fadlth8 lo loon virtual appointmen18, or u? lo QOgn￿¥? is8ws wll lack the capadty to txganim and •ngag¢. In response, the chanty has continued lo providti And gr￿ lo eMLwe thgt we can r•a¢h and Jupport our benef￿la￿s, kn any way pos8ltAe. Due to this owling Siiuation in the wder care sector. the charrty took the deci￿on to expand the Nats'onal NF Helplne semee from Iv*t• to thrrt d•y$ por wo8k from the end of2022, and now Iso operate¥ a triage bookiThJ system ￿ the interyenln9 days. We COnb"n￿ io monitor demand to en8ure the 8erviGe meets the needs of the community, and adapt a8 fvnds pernlt The charlty conflnu￿ to c¢n¢entrai• ￿ Its ￿traI t)¥¢ •¢r¥lc•8. hwe 4180 cMllnuod lo #trengthon and develop our core support Slrudurns lo •n$Ln that we mgintain best poMibl• 8UPPOrt and advise 8eNi¢eg for onyone affectsd by NF. We are col￿tantty in rWiab'on8 With NHS tntsts artyjnd the UK dI￿U#$ing how wt can roll out our support sorvte8 kn the most e¢cmc¥ni¢ arhy officlerrt manner po88ible. Fundlrva AS the charity not roc8ivè st*utory (* kKal aU￿rity f￿￿Ing. the bu￿ oflhe charity's co￿$ from charrtable gNiry and monies raised from events. Fortunately most major events. eX￿p1 for RideLondon, have retumed to the calendar, hov•Wtt the commw)ty'$ ongoing fear of mixing. means that communty small scalè fundraising has als but disappeared. This has had a signrfKart adverse effect on inLMJme streams. As ￿ fund a no￿￿)rk of Sp•o4isl NF Nur8•8 Advi80rn {Spo>4ist Ad¥isornl, polw requires u$ to maintain 8 minimum of 12 nKinth$ of ￿8•￿e8. The ¢h8rty ¢￿tinUeS to react quickty to the C(￿StraInts placed on it by the current economiG dim*, and by the latest Large sethr pay aYrard$, and the increase in National Insurance Contributions. This has minimised th• impact on the levd of reserves held over the last few fina￿lar y8ars, and at this lime, wa we confident that ￿ arn th to co￿"nUe to mamtal) our reger¥eg polw. Ouks The Neurofibromatosls Assoclatlon Report and Financial Statsments Year Ended 31 October 2025 Plan8 for Fuiuro Su8tslnablllty Post pandemk. tr* chanty VAS forced to Ter￿n$￿￿ our str*gic pLan. the Bowd implemented a strategy group, vthich continues to look at howthe ¢harity ¢an and expand its serlw, in this very te￿Ing e￿n0M ¢limat•. when deM￿d for our 8er4w have alcryside the hLwe hike in delNerNig our 80Thice8. Key Strat•glc Almi The charity's kèy strategic aim$ Gontinue to ￿. Increase awareness arKI under8tandlng of NF. part￿￿lIrtY amongst medical PTofesslonals. Provide and ff*aning￿l suppc*t and guklance to th(w Ir4iNJ *ith NF and their wider Support n8W. Promote and support research inlo NF. Our frKu$ ¢ontlnues to bo on l)OW V•* can Streamline. yet exp8￿1. wr seThi¢os", cfyordinat• our work with all partners Induding re8e8rch lJo(lies'. ond xnprove th• educatlty) olthe medlcal professbn. In a survey duriTrJ th• report￿la porK￿.. 93% olrespondents wanled us to o)ntlnue lo rnlse awarnM&8 of NF wlh tho mod1¢alprofg￿I0￿. Our almlg to ensure that people are #b￿ to 8cees8 accurat• and twnety othce and supwt as •ffo¢twety and Offieièntly 88 po￿1￿, whother or not that i¥ from the Ch￿ty. The charity's staff and medical continue to promota the new rnedlcal hub on our I￿*b$ll8. ea8y ￿¢0$$ to bcture•, guhjellnos ond other Telev8nt lotsls to •du¢ats Vthidor •lli•d hoaithor• Wd•s•￿1•. The charfty also Strives lo find ne•V W8y8 of *￿>￿ing. indudlng GlIn1￿, appointsnents and meetings. Although onllne services are not wactKal for all (for example, patients ¥&ith cognlbve impalmient and knming i8suesI, y￿ can $ee that improved onlint conntdivty and familiarity lèads to red￿ed ddNory costs and greater efficien￿. In the fvture our inlenbon is that a balarK• Of(￿line and in per8M vill alkn¥ tho charty lo provth 8ervtt8 to more Feople. 8pocla118t 8upport N•t*wk The chanty wlll continue lo malntsln h s￿dalISt Supm Nthwxk of Nwses & A￿8(￿8 Ispgciallst Advisors) and continue lo #eek lo identfy areas of thè country where engagè and 7hDrk with the NHS to makejoint •PPointm•nts. The charity Gurrenuy funds a nety•vrk of ten Speck4list Adviscff5 rn the UK supporting posts in NewGastb, 8lmingham121. Hymouth12). Liverp￿1. Scthmptrjn. Sheffield. Leed8. and Wales. and h88 an a880ck7tson wrth Northern IrelarKI. Urrfofbjnatety. the po¥t in Scotsnd IB #thl vacart as despib ¢yJr be#t tffort8 to •ng4y wlth the clinical communbty, there apF￿r9 to be a blanket ban on recruitrr*nt In the region and as an interim. we a COn￿nuing to I￿rk ¢108ely wlth the Sco#lth OTre for Rarg Diaeases, th• National Hdpline wjrks cFosely Clinical Genelics at the Queen Elizabeth Unlversty HosF4t81 ba￿ in Glasgow. Vle ￿$alle that the Brf8101 post. after several years in the plannry. V4ill be up aThl rurffting in 2026. Two SFecialist NF Nurses OK￿le the Nerve Tumours UK National He￿)line on a part time basis. which provide8 advice and connects pe￿Ie affected by NF wilh relevarrt wxtical l*, either in theK comrnunty. or in clini¢, across three days of the worknng week Cffi intefim days. the head offKe staff operte a thage helFdine. booking in apw)intments or r8feThing to rngi¢)nal Spgciatist NF NuTres. We aim lo Introduce fve new posts during the r*xt fina￿la1 year in parts ofthe UK. Mthere there has never been any Tegional support. However. this timescale totalty depends ￿ the effectrrferes5 of the intemol med)anism$ of th• indivtdual NHS Iru8ts, can beeam• long and proeesses. Eath of ow current Posts supports OU14 The Neurofibromatosls As$oclation Report and Financial Statements Year Ended 31 Octob8r 2025 tse￿en 180- 3.420 patsents per year via dir#c8. ￿sit$, sthyJ n￿til￿, *tirkplace meetings, advisory s•Mc•s, telephone consultations. The rcle of Specialist NUrse￿Ad¥￿S is drrt5e. have ha(1 excellent feedw from the families supported by ourl•am and it 1$ ￿ain to see thal for th050 frami1￿. th• support re¢eive from Ihe Specialist Supwl NetrL)rk Is p6￿thI in helwng them tr) cope wth NF. In & recent •UP40y compU•d durfn9 th8 18portlng po￿0d.. 70% olth8 NF communRy w8rted the (*aty to NKrease av8118bNly dsuAx*t by having moTr Sp8clallst Nurses 8ndA0￿￿￿. Funding, and expanding. th¢ Sped•W Supwt Nelwork *ll continue kn be the k•y rol& for Nffi Tumour8 U Over 60% of patients vAth NF1 have d￿¢￿tha. and apyoximatety are registered ￿ disabled, as are 75% of those pats'ents dlagnos&J NF2. H(Mwer. mrene88 of NF arxoss all profession$ including the medical prole831on,18 low. Our experfence Is that thls can ￿ lo s¢)me chlldren t*th NF $truggling at sthool. Inappropriate, or nonvextBtth)t 8upwt Norvè Tumour8 UK offern a $thool$' advl80ry iNFom, operated by our Speciali8t Support Nefv*vrk. ￿ere engaged, the team do* with teachérs, SENCO'S. albed heathare Frfofe88iona18, and parents, 8UPPOrtlng tailored leaming plans. and 8ugge8ting m8chanS$ms for fjnhanc4ng th• chlkl'$ eyriencè at 8d)ool. A8 a r08uIt of th• pand•mlc, V•* have fourKI that VK w Illl operate INFL￿ effectfvdy, albert ￿rtUalty. and In the year8 8lnce we have found that more ailied healihcarn wofe8sk)nals are *illM)g and abbg to i￿n the iNForm meetings rf they are held virtualty. Nerve Tumourn UK conlinut8 lo offer an exten3r4e range of lilw8lur• and Snfomwtlon, for lay people, whid) IJ al•0 d¢ly used by OIIW healthcare profo8swMth Ihg UK arKI fvr#)or •ll•ld. Our bafiets and pamphlo1• ar• subject lo constant f￿•W and updats. Wa contlnue to expand our INForm progrnnThry, I￿Ing dwnowd *41h NF to reach thelr go•￿, with a 8u¢¢e¥slul and rKelved ofthe'iNForn) Your Uthtr8Olf r We contSnue to ralse awaref￿8 amongst the wlder mèdtil wthsslonab C￿M￿nNY, at every opportunty, be il our Specialist A¢fvisor8 gNlng Idk8 to local wp8 or m41mbern of the Hoad OIFth S•n*)r M•n4emont T•8m 8tt*ndlng nalion•l conferenc￿. Medics are invite(I to use Nerye Tumour8 UK Nalional Hdpline a8 required and to •ubsrJbe lo IM oTrllno Meojcal Hub. Charlty Reach Th• N•rve Tumourl UK H&gd Offi¢è tèam corthue to *Y)rk excepti￿alty hwd. golng above and beyond In response lo the fallout from the *t fthv years. arby tho Board aro again very gratefvl for their effc¥ts. Key workstreams include the constant development of I￿r *tbsite. in Parti￿*[ the medtal seGtlon, the researth hub, and thè collaborativè useful ￿￿n￿tiOnS soction. Wo rxeNed oxtremety poth feedback on, and after, the launch of the medical sectlon. and have seen h(Mf this Mwoves ￿**J&AS erg4err*nt WTth ￿￿diCal professionals, particulady GFYS. Social media remains an important and grThiing aspect ofthe chanty's communicati.ons and marketing strategy, and we continue to see healthy websrte traffK, despite an increasingty thalfenging digrtal landsGapg. Dedicating ongoing tim8 and rasource to these area$ en$ura$ th* ve meet our communications 9081s of 8erving the communty, supporting the community al￿ raTrsing awareness of Y￿h1n the c(xnmunty. Facebook r8maln$ our ts"9g￿l SO¢bO1 r￿"0 channel strong eNJagemnL Throughout the financial year, our updates re¢eived just under 4 million ￿e￿, vknite also saw more interath.on and engagement from our followe with a 80% increase on the prewous year. Our totsl frA50v￿ng grew by 4.5% and now sits just short of 8, 500. Our other primary KKi81 medFa channel is Instsgram. vthere visual storytelling tskes a greater To￿, giving us the opportunty to share and $h¢)Kase the real-life stories of our benefickaries. Our following there exceeded 2,400 and throughout Ine year we reached jusi under 138,000 peo￿e. Rv¥ UK Tho Nourofibromatosis Assoclatlon Roport and Flnanclal Statements Yoar Ended 31 October 2025 We also host a private NF CcrfnmLsnty Group on Facebook, of Cbrix 1,800 m&ml)ers, there patients or thew carers can talk, ask questions and share experien￿ in a safe space. Through the year, our websrte received over 181,500 vivws from almost 52.500 users. ¥thlle the numb•r of subscribers lo the monthty NeFVe Tumours UK ￿e￿Ie￿er8 gTVW to cyca 3.47S. Dudng Wodd NF Awareness Vkek in May 2025, we Saw malor high p￿.rtts in our yeaty engogemenl totals.. thr￿gh the respective NF1 and NF2 days," the ann¥Jal Shine A ￿ght campaign, ¥thich saw 178 strategic buildin9 and landmark$ light up in blue in supw(' and ¢wr annual digttal media campalgn. Th1$ years campatgn grabbed publl attenbon ￿th a cheeky and thoughlyovokn'ro queslion."Do Charty Ads Get On Your Nervesf, rai8ing awareness of NF in muf(iple strategic l¢)¢ations by nnning across 25 major rail hubs, and reaehing a footlall of some 2.3 million peo￿e. A tsmpaign running in paralw on FaceBook YouTube reached over 970.000 users wth 1,150.000 plus impre￿On3. and re8ulte(I In 531 Ilnk (**B M t1￿ ￿mPaIgn. Th8 aoh4ert8 have 8180 8een 49.000 plu8, P081 engagements. We also Con￿nUe to Beek to devolop and •11￿9￿￿ our h￿1 partnernhlp¥ wlth organisallon8 Including The Conlr• for App*aran￿ Re3earth. The Genetic Aliance, and Neurdogical AlliarKe. We have anoth•r medical Inf￿ation day planned lor 2026, *thlch be both Iv￿$treaM8d, to [￿h as many of the communty as po8sibLg. The contlnued r￿lO￿t of LxJr• s•nrfc￿ thrwghotrt the perknd Is an ￿¢•lIent Yelledlon of the comblned efforts and dedlGation of the Specialist Nets￿rk of NursealA(fvi80rn. our men*ern, supptytrs, head office $t•ff aTha the M•dlcal Advisory 80ord. th• Tru$t••$ we ¥•ry grnt8ful fty the exc¥ts'on•ty h¥d *rrk. whKh has been put ￿t0 the charfty. There are no immediate finandal concem8 fcrf the cknrity. although the ￿rreftt economic dimat$ and upheav$l remalns of concern. The Iru5tets maintain that NeThe Tumours UK is still CUrr￿tty on track to m•81 it$ long-temi 8tr8tsgl¢ and flnanclal targets. Struthro, Govornanc• and Managem•nt Nerve Tumourn UK is a Ch•rit8ble Cthnpany, limited ty guarantee, incorporated on 30 June 1999, and registered a8 a chanty on 5th January 2000 (wovlousty 284653 reglstered 1982) wlth a mèmbership b88•. The company wa8 èstablishéd undor a Momor￿d￿m of Aswiabon, whth e5tabhshed the objects and p￿er$ ofth• Charitable company arKI is governed under ts ArtKles of As%Kith. In the event of the CLwnpany bew %￿Und up membgr8 are fequlred by the adopted Conjlrtuhon trJ (x)ntrilxrte an amount not exceeding £1. The dIrec1￿ ofth? conwany are ablo charity tnmteej the puryJo8e8 ofthamy Ivw, and under the company'8 Articles are known as members of the Board of Trustees. The Board of Trustee$ m•rfs at l•a8t four times a year and is responsible for the strategic direction arKI ￿licY of the tharity app(xntwig auditors to ensure financial compliance. Medical Inpul Is gfven via our Medical Advisory Board. a rePre￿￿tiVe olththich on the Board of T{ust￿. Trustees are 3eleGted for ther of NF arnl the wofessw)rrd. that optimize the knOW￿dge 8nd ability of the 8oard. A sub group ofthe ofTnJstees, the Fb￿n￿al Athrys(￿ Group, WKI Includlng the CIHrtty DlreGtoT, ha5 been estsblished to ¢CfftKler and tr* fmaTh>al aThJ investrwrt ofts tharity. Modical Background The charty'$ me￿)erShiP is rrb* from faThNltes affected try NF. NF1 affects 1 in every 2.500 Fwple wodthwde. which means that there are more than 25.0￿ in the UK.. NF2 is much rarw, 1 in 35.000 affected woddwide. wrth 1,000 in the UK, and there are approxHnatety 500 people diagnosed wrth SM. An affected [￿On of eithef sex h88 8 1 in 2150..501 chance of passkng the altered {abnom81l gene on to thelr children. However. everyone has a risk of havry an affected ch￿d because 50% of all those affected by NF th• first person in their f8mity lo be so affected. Tho Neuroflbromatosl$ Assoclallon Roport and Financial Statemonts Yoar Endod 31 October 2025 NFI is a hugety variable e0ndrt￿. vA)ich has the potentsal to devekjp a large number of complications. Some people wth NF1 having sknn invofvemenl but Wenlial complcations indude.. specffic leaming dffiuJltie8 and behavloural problem8- which affects about 60% of all peopk with NF1', high bkjod Pressure {hypertension).' curvature of the spine {8coliosisl' maltornation of the I￿g bones (tdcM the kr￿ and below the elbow) {pseudarthrosk8}' large benign sk*) tumours IplexifNm neurofibroma81.' tumours on the netve8 of 8ight {optic gliomal.. intemal, spinal and brain turr￿S- arn usually benbjn ho*•ver 10-15% of wopl8 VAII devglop a malignant tumour related to their NF1. The mts5t swnrFtcant i55ue for people *ith NF1 is that the ￿cuThen¢e of these Complications cannot be predicted even wthin familbes. Many people with NF1 also have low Se￿-eSteeM and thi8 can cau8e problems forming frberMIBhbpB. whwth lèad8 to WO￿1￿)n. NF2 ¢on3i8lenlly causes more probjems than NF1. it has an increased risk of devel¢)ping brain bJmours. Although these lumours are benNJn. the position in vthich they grow cause maj¢x problem$. The most common srte 1$ on the hearing and balance neryes cau$irvJ problems with deafness and coordination. The sense of isolation from deafnè$$ onset in adutthood can be imrnense. Peiwe NF2 may 8150 d8vfjbp wnal ¢ord tumours. wtth their ¢)wn 8ignffic8nl complicatk>ns. NF18 an unpredktsble arKJ vWlab￿ ger* 0￿dI11)n th8t can allecl all pa￿ reg￿d￿$ o1gerKler, raco or age. During their lrfeb'me, palEnts rnay see a wide range of I￿alth arKI care professionals. I￿th in eommunlty ar hosptsl setting8. The Spwalist Ath'sor¥ act as a pomt of refwen¢e for familie8 helpng them nawgale through routine planned event8 and at times olcrlslg. E88erthlty. their role 18 to help peop￿ to lèam lo Ilve wrth Ihetr diagnosis of NF and to ewip them *ith the knoh4edge ofwhon. Tthtwe, to s••k holp. M nKessary. As a mult￿$Y$toM condit￿, NF ha8 an Impact on many arnas ol peopl•'s I￿8$, nol lu81 he•lth. The Speck81181 Advisors take a lead lo￿ in liaison and arfvo¢•cy with htr8Ah. e¢kKation, al￿ social $ervlc•s to 8UPPOrt the quo11ty and ¢ontinuty of care for famil￿ affocttd by NF. They seek to develop a sèNke that 18 professional, timely and regponsive lo need. Thelr geth.ng may be ch'nical. vij￿r￿J families al hcffne or telephone ¢ont8Gt. The ouallty of the Telallon8hip8 they 08tabll8h18 tyrt￿l to thetr effeclfven688 and may ¢￿ttnu8 over many yearn. Flnanclal Revlew Incom• G•n•ratlno Actfvlll•• Our ttead offtce leam ¢onlinue to devebp Innovaove vlriual fijndralslng kleas aTrJ 8Lwr¢e new income SI￿am$ at every OPFQrtunity. Ouring the perio(1 Ihe charty had income resources of £555,411 and a total exwndrtura of £546,010. r••uttlng In net re•oW￿ of£7,401. This ha¥ re$ulted in lotsl furKls of £656.018 bdng camed forwwd. Of thbj figw8 £28,88118 r05tithd to proJe¢ts 86 8peclfled by the lemM and corwjlbons of certakn donal1¢￿¥. InYo1b))•nt Polky The charity's fvnds have been invested in a mixlure of one year f￿ed income bonds aThJ short-temi dep￿rtS this ffinanctal year. The Financial Advisory & Investment Grwp, established in kle 2022. reportmg lo the Board of Trustees. continue lo remewthis posluon and fvrther irNeslment OPP￿inthS. to ensure all income poten￿8115 maximi8ed, vlth nlnimum risk. We give carefvl c￿$[deratiOrt as to how can make our reserves generate an income thtr charTty and have considered a number of options arKI irrfL¥mal advi￿. At present. given the cwrwrt rate of return, the costs involved In investing, and the inherent ri5K wa have ￿ntinU#d to d¢et to hold the reserves in a mIxbJ￿ of short and medium temi deposits with a number of barths. Htr•mer, continue to M￿lIOr al other options available. Ro•or¥H Pollcy and Golry Conc•m Reserves are r￿ded to bridge the gap between the spending ond r￿l￿ng of Rico￿ and to cover unplann8d emergenw expenditurè. The Trustees Consider a minimum of £500.000 is the ide81 level ol rèseryes and being suffiLy8nt unreslitted resefves to fijnd Specialbst Siwyt Nth(Kk for a minwnum of fv*lve mnths due to the The Nourofibromato6i8 Association Report and Flnancial Statsments Yoar Endod 31 October 2025 number of murtkyear contr8ctyal C￿M￿l￿￿', dWit￿$ administrati￿ and operaknry costs for at SLY months. The Trustees consider that adequate rex)ur¢e$ ¢onlinue to be aval￿ble to fund the xtivrbes of the charity for the forg8998t4e futu￿. The Trugtees are of thè view that the thgrity 1$ 0 going ¢on¢em. Koy Exp•ndliw• Ar•a• The key areas of expenditur• ¢￿￿{nu• to b• th• opwalltyd ¢¢8ts ofth• Spodalljt Supwt Netrmwk of Nur8eB & Advisors. Each year, ￿ aim lo raise sulfi¢ltnt fur￿ lo rnaintsin the lI￿￿e months. Teserves. If the chwty provides further funding for th8 Spedallst Netrmxk. th18 tsxrth￿. the required ￿￿e1 of r88eryes. Is likety to Increa￿. Publlc B•n•fft All our charttable actlvlile8 I£￿# on Ihè1fr4es of tho8e affethl ty NF and are Ufthrtaken to furthw our charitable purposes for public benefft. The Trustees have regard lo the Charity Commis8ion'8 guitlance on the need for chariti￿ to dolrnr a public b8n•fft and have fAimplied thg dLty in secticm 17<21 of Charilies Act 2011. R•crnltm•rt Appolntrn•nt & Indu¢llon of Bo•vd olTru•tw• Under the requirements oftr* Memornndum •rKI olAMocl•b'on, the (*)evthtrd longeil stsnding members of the Board of Tru8ts98 ¥hall reb're or put th9m¥8￿ frywwd f¢Y r•-eleCti￿ al the next Arinual General Mèèting. Th maximum tim• 4 trustee can remaln kn FMt * t•n y•arn, that Ilme may ￿ •xtendod for a •hort by the Board on an ￿reP￿.1)nal basks. The 808rd ofTru8le08 seeks to recruit a mix of I￿￿ne$s, mo￿￿81 and patwl expertise, athough preferrèd, there18 no requirement for a Board member to have any diffKt or indirect exwience of NF. All Tru8to8s, upon •*lion, m••t wlth the C￿r to dIS¢u￿ and r•qIrnn￿l ofth• Td•. 8t•tsm•nt of Tru•l••• r•¥￿IbI￿1•• The Twstees, Wt￿ are also tr* directcrs of the NeurofitKomatsth Aeaodatth for the pury)08e of company law, are responslble for prepadng ￿ Trustee8 RepL￿ and the fina￿al slatemenl8 in ac￿￿(larKe vAth FRS102 and the charity SORP IFRS 1021. The Trustees must ncl apkYov• finan¢ial slat•m•nts unloss they arn Satisfied that they give 4 tru• and far ￿eW of th• stal• of affairs of the ehuty at tho •nd ol th• fin#r*A*I y￿r and of tt8 iurplu• or deficit for that wrtod. In doln9 $0. th• Trust￿8 aro rwcwblo for. ielecling 8uit*bl• 4x¢ounting and th•n wly Ih•m observing Iho m¢thcx1$ arm1 pri￿lpleS kn the Ch8f6lM SORP. making judgements and estim8tes that are reasona￿e aTrJ prudent: preparing the financial slatements on the g(M'ng ￿nCern basis unless il IB nol apprwate to a￿ume that the ompany V*ill continue on that basis.. arx1 the maintenance integrtr of the ¢orptyalo arKI financial wiformat*M induded on the charity's website. The Board of Tfustees is re8pon$blg for maintaiThn9 kYLW ac£ounbng records vhmch disclose WTih reasonable accuracy at any lime that the fin8rKial Statem￿ wth the CompanM Act 2006. The Board of Trustees is al80 responsible for safeguardkng the assds of the charitatAe cornpary he￿e for taking ￿$¢￿able 8t•ps for the prevention and detection of fraud and other ryul*iti"es. Mombgrn of thg Board of Tn*to0• Member8 of the Board ofTwstee$, threctors kylhe purpose ofcompany knv. and Trustees for the purpose of charty law, serve(1 dunng the year and up to the date 01th￿ rem are set Oth ¢)n page 1. The Neurofibromatosis Association Report and Financial Statements Year Ended 31 October 2025 AudltorB Davfjd H¢Jward was 8pwnted as audrtor uThJer secb.on 145 of the Charilies Act 2011 and seth'on 4411 Ilcl of the Charities and Trustee Investment IS¢oland) A¢t 2005 and uThler the Companies Act 2006 and rep(Kt in accordance vAth the Acts and relevant regulatiorts made LY havrfj effert thereunder. In 80 far as the Tfustees are awdre. at the time of *Jpr(Ning our TnLqtees' annual rerwt there 18 no relevant infomiathjn, ￿NIg needed by the aiMJitor in connection V•ith preparin9 thelr repor( ofvthich th aLthor 18 unaware,. and the Tnffjtees. having made enqukie8 of fvllTh Trustees and the thafity's auditors that they ¢)uglrt to havo individualty takon, have •ach tsk•n all $tV8 Ih•t hW8he 1$ obliged tr) tske a$ a Trustee in order lo make themselves aware of any relevant audrt Infom￿ and to e8tsblMh the aud6tor 18 aware of th8t Inftymatfion. Small CoM￿nY provl#lon• ThL8 report has been prepared In tre specaal wo¥lsi)ns tr Sm￿1 companles under Part 15 of the Companle8 Act 21￿. Approved by the Board ofTrLMt889 on 10 F8bnwy 2028, and ¥gr*d on ts beh811 ty.. Rlch*rd Good• Ghalr of tho BO1￿ of Tru•t• & Comp•ny S•¢r•tsry Jon•th•n BnK• Vlc• Ch411 The Neurofibromatosis Association Report and Flnanclal Statements Year Ended 31 Octobèr 2025 We have a￿lited the finarKHI slaterwts (rf The Neun)f*mr￿ts AAsLxHlion for the year ended 3151 October 2025. ¥gt Qui over page¥ 14 to 25 roport, conyi8e the statement offinancial activths. the balance aheel 8nd the related nrrtes. The finarhrial rewxbng frwn&4th that has been in their preparat￿ 15 appEicable law arKI the Finawal ReportiNJ Stantjard ap*ble ￿ the UK Re￿￿ of Irel¥#l (FRS102) {effethe 1 knuary 20191- (Chartties SORP (FRS 102). Oplnlon ¢)n th• fln•ncW •t*t•m In our oplnion thè finand81 stateménts". 91v• a true Ind fatr vlew of the stats crf the charltable compan￿8 affalr8 •* at 3111 Othlxr 2025, and ol tts incoming resour¢ts and applieation of r¢souw. knr the year lI￿n endgd: have been property wepared In ac¢ordar*ce Unrted kn"ngdom Generally Accepted Accounting Pracb'¢e,' and h•v• bfj￿ pr•p•r•d in •¢¢tydoru vthh th• COMp•ni￿ Acl 2006 and Charitses and Trust•• Inv•8tm•nt (Sco￿and} Act 2005 and regulakn 8 of the Chanlle8 Ar£￿nts (Scotlandl Regulatlon8 2006. Ba8lB for oplnlon We conducted ow audl in ac£othnLYJ vlth Int•mthl StsrwJwd8 on AudKlng IUK) {ISA8 (UlQl ar#J SP￿￿￿ble law. Our responsibilities urM1ér thcth slandards are lurfler d•s¢n"￿ in the Auditc¢s re8p)Nbilrtth for the audit of the finoncigl $t8ltmenls section of our rewt. are independerrt (rf the ch¥iiabl• cL¥npany in accordan¢e with the ethical requirements that ar6 relévant lo our aud* of the financial statements in the UK indudNig tho FRC'S Elhl¢al Stsndard, #rKI wè have fuffilkd ¢)ur other ethical rew8tbUth8 In vAth the￿ rnquiremwrt•. V¥* ￿11￿¥• Ihal th• aud e￿Ience we have obtslno(I16 8ufflryent arKI •pprcylat• lo for our opknv)n. Conclu•lon• rnl•tlNJ to golng cone•m In audlting the flnanclal 8taterMnts, we Iwe con￿￿8￿ that thg TruBto••' of th• gokng concwn ba818 of accountlng In the prepara1#￿ of the finarval Stat￿n￿ts is ¥)propnate. tha( Ir￿1ViduallY or coli•¢tiv•ly, n¥y cast 8lgnlftant doLI)t on th& d￿n￿8 atxlty to C￿￿'nUe *• a going conc•m f¢r Our respongibilthes and rnApcmknlHllos ol tho TnmtO￿ rejwx to ¢(*r4m aro dexr*Ad kn the relevant Beclions ofthls rewt The other Information (xjmprises the inftrm¥llon if￿￿￿&y kn the wnual re[￿. kK4uding the Tw8lees' w*p)r( othw than the finan¢ial ¥tsterrEnts and ow a￿111￿8 report thereon. The Trustees are re¥>oroible for the other irftimalion contained ￿￿thIn the annual reF¥Jt. Our Opini￿ on tr* 8tstetrthts not cover the other infomiatKJn and, except to t￿ extant empw stated in our reprrt ￿ OJ nrA exp¥e66 any ftjm of aswra)co conclusion thereon. inconsistent wth the finaneial ststenvrts (* oblained in the course of Ihe audit, or crfheTh¥ise appears to be matefialty misstated. Ifwe iderthfy such n*ia #icons￿1￿￿￿ ￿ apparent Materi￿ misststeffthts. ￿ are required to detemiine whether this ￿yeS rise to o Mat￿31 misstalement in the fmanC1￿ Statem￿ thwnsefves. ￿. based on thè reFrf( thatfacL 10 The Neurofibromatosis Association Report and Financial Statemants Year Ended 31 Octobor 2025 In our oplrdon. t)a*J on the w)rf( undertakert in the courne ofthe a￿111.. the 1nfrffi￿ given in the TnMtee8' Report forthe fin￿￿*1 year ftyvthith the financial Statements afe prepared ￿ eonststent with the finanaal ststerrents.. and the TN8tee8' Annual Report ha$ been ￿epared in &c4)rdm *iih applic**le *al requirements. In tho Ilghl of our kn￿￿￿￿9* and urthrntsndkng of tho thwifabl• ¢xmpany and Its •nvlTonment obtslned In the course ofthè audit. we have not Klfjntifiod m*erial m￿StateMents in tho Trustse#' NA￿Ual Rèport. We have nothlng to report in respect of the follcwA'ng rnatt￿ wthere the Conwnies Aet 2006 ar￿ the Charitses Ac￿unts (Scotlandl Regulal¢)n8 20C6 requlre us to reF￿ to you rf. in our OpinK￿." •dequale and proper accounting records have not been kepl or rdwn8 adtyuat• for our audrt ha￿ not re¢eivod from brar￿h•S not v18rted by ￿. tho finan¢ial statements ￿ not kn agree11￿ thlth the re¢¢Kds rettm8', certaln disclo$uMs d Trustws. r•munwation speow by law are not made, we have not T8￿1ve￿ all the Informglkn and 8xpl8natlons we rewire for our audlt. the Trustees *tre not entitted to prepare Ih? fina￿141 jlaterwts and the Trustees, report In acCOrdar￿ wlth th• $mall compfjnKg•' reglme. R••poMlblllll•• ofTn*t••• As explained more fulty in the Trustees, res[￿fish.11￿s $tat8mont sèt ¢>Jt on page 2 to 9, the Twslee8l￿Q are a180 the direcbrs of the th9rrta1￿e company purposes of company 18wI are re8Fonslbl& for the preparallon ol the flnanaal Statements arml for belro satisfied tr￿1 they gNe a INe arKI fw'r vlew, and for such Intemal control as the Trustees detern￿ne 1$ ft￿¢￿ry to enabb the prepwats'on of financ￿1 8tatery￿nts that are free from mateilal misslalemenl, vthethor due lo fraud or effor. In preporfng the financial statem￿, the Tru8lee8 are re8poMlblo for 0J8e881rKJ the compAny's abllty to conunue a8 going concem. disclosing. as applKat)le. matters related to going concem and using the goiThJ ¢oncern basis of accounlirwJ unless the Tru5t¢es eithw wrtend to IKiuidate ts cL¥npany ￿ to cease operations. or have no realisJc alternattve to do so. Audhorn, vMpon•*llltl•• lorth• •udlt olth• trknnclal •t4t•m We have teen apwlwiled as audltor Lmder sethon 145 of the Charilies Art 2011 aThJ sectlon 44111{c) of the Charttles and TN8tee Investrnent {Scodand) Ad 2fy)5 and under th& Companw 2006 and report wi a¢¢ofdanc• with the Acts and relevant regulations mad8 or hawng gffg¢1th8mth. Our objeclhes are to obtsin reasonable asSurar￿e about *l)elherthe ftnanclg18lat•7￿ts as a Ythole are free from material misstatement. whethèr due to fraud Of •rror. and to issue an •uditorf$ rèport that in¢ludes our opinion. Reasonable assurance is 8 high level of assurance. but is not 8 guarantee that an audrt condueted in accordance vlth ISA8 {UK) vlll aw8 detect a matwfial m0$8tatement **en 6t exists Misstatements can arise from fraud or error and are consmlered material rf. kndividual￿ or in Ihe aggregate, they coubj reasonabty be expectsd to irffluence the de¢isiorn of ulers laken on the baw ofth¢se fin8ncsal statements. Irregularit*s. I￿udIng fraud, are inslartts of n£r￿comp￿ with I￿ regulations. We ¢Jesw procedures in line wlth our respon&biiattes. (Mrtkned above. to dete(x n*rial n4ssiatements n re8p*i of ireguLgrities, indudlng frdud. The Tho Nèurofibromatosis Association Raport and Financial Statem•nts Year Ended 31 October 2025 Our approach to idenbfying and ass8sswvJ ts risks matw*l mNtaIe￿ in resped of iwegulariii88. induding fraud arKI nonrycomplia￿e with la￿ aThJ rejkn. as foltrK". th8 •NJag•mwtt partner ensured that the engaggmert team collecll¥dy t￿￿ the approprlate compelenG•. capabilities and thlls to identify C￿ re¢ognise rv)rpcompli¥Ke wtth applica)le kn¥s and regulallons., we identified the law4 and regulakn8 app&cable to the crynpany through dixussions wrth TNstee$ and other management. ar￿ from (xw coftNn￿l knvArfedge and ewience of the d)arlty sector.. we focused on spedfic laws and regulations wthi¢h cons¢dered may have a di￿¢1 material effect on tho finanaal statements or the operations of the company. I￿}LK11n9 such as the Chanties Act 2011, taxation gi8lation. data protect￿. Iwllh and safety legislation.. we assessed th• oxt•nl of wilh the and Tegulalions Id￿ts￿•d abo￿ through m•klng enquiries ol managamthrt and inwtirvj legal crnF¥)r¥j•n￿,. arKI hJ•ntffi•d law8 and regulation8 communKated vAItrAn the audlt toAm regulorty and tho t••m rnm•lnod alert lo in$tance8 of n¢NKO￿lar￿e thmughtyth the audiL W• assessed the Susceptiblty ofthe c(ryany'8 finandal Statem￿ to m•tsrid misstatement, induding obtaining an understsndlng of htyw fraud nlght cKcur, by: maklng enqUIrf￿ of managen*rt a8 to Ihoy c4)n9￿ thwe w48 8u8ceplblllty lo fraud, thelr knowAedge of actual, SUBF*ctsd and alleged fraLKI' considering the intwn•l crythl• In to mtyte offrwA and nonvcomplknce ta￿ and r•gulalion8', and To addr•88 the ￿fjk of fraud Ihrough m4n4emant bws and ovorride of c4>ntrol8, W•.. p•rfomied •natyts'cal ￿0Ced￿reB to identity any urKwal or urnxpKt•d relauonthlp., tested loumal entrles to hlenty unu$u81 transa(ai)ns,' alsesged wt*lher judgi)m4Mts and assum￿rn m#d• in d•iwmining th• wcounting ••tim•t•• s•1 out in Not• 18 V**re Indi￿￿¥• of pclential bi•s', and knveslgated the ratiMalo bthirby signiftant or tran8action8 In ro¥pon¥e to the ri•k of irr•gul)rities •rKI rw<¢)mpIk9r￿ *ith laws regul•b)ns, d•swJr￿￿ pro¢edur•8 Ich In¢lud¢d. bthw•r• not Ilmlt•d to.. agrfjeing financial ¥lalement di8¢k)8ures to ￿r￿k¥j doGvmwrtakn,' readlng the n￿nuteS of rwelSrvJs oftho8e thorg¢d wlth 9￿•ManCe.. quirlng of Trustees 88 lo xluol pot¢nbo1 Iltsgatsw and 4olm8.' There are Inherent IImita￿on8 kn our audit procedurn8 above. The more removed that and rogulatr'on$ arg from finondol transa¢llon$, Ihe l•ss Nkety11 Is that we ?*￿Id become aware of nM4ompllan¢e. Auditing standar(Is also limrt the audit pr￿8￿u￿$ requifed lo identify norFe￿￿p1￿nce with laws and regulation$ to ewuiry of the directors and other management and the inspeclion of reguLqtory and legal correspondence. rf any. Material misstatements thal arise due to fraud can be hanler to detett than th08e thal arise frcrfn error as they may Involve delibeRts corKealment or coNusion. A further de9(¥ptr￿ of our respomibililies for the of th& stat•m•nts is kKated on the Financial Reporting Council's ¥￿bSite at [www.fr¢.org.uklaud*or5rew*>iliaosl. This desuwion for￿￿ part of our auditorfs report. other mattgrs which are rwuirgd to addre In the prewous accounting period, the trustees of the charity toc* advantsge of atwjit exemption under Seclion 477 of the Companies Act 20C6. Therefore, the prior per￿￿ finanual statements were Mt sJJbject to aud6t. 12 TuMowPS The Neurofibromatosis Association Report and Financial Statements Year Ended 31 October 2025 Uso of our fvport This report is made solety lo the d￿ritable corryjany's members. as a body. H) ac￿nIance wlh Chapter 3 01 part 16 of lh¢ Ctynpanies Ad 200e. and to the tharitable company's T￿￿tee￿, as a bijdy. accordance with Regulation 10 of Ihe Chartbes Accounls IS¢oUan¢Jl Reg￿LationS 20C6. Our audit has been undert8ken so that we might State to the charitable compaThy'$ members and Tfustees those malters VIE are required to state to Ihem in an auditOT'S report and for no othei purpw. To the fuHest extent perrnitted by law. we do not accept or assume responsibilty to anyone other than the ch8ritatAe cunparry and. Ihe ch8nt*de corrrf)wry'$ nxn*ers a$ a Wy and thg charitable cc¥npany'5 Trustee¥ a$ 8 boty. our aKlltwyK lor thi8 rewt. orkn the opkn1￿ we h8¥* Iofmed. 8lnod Dongol FCCA IS•nlor 8tatutory Audltor) For and on behalf of Davkl Howard, Slalulory Audllor 1 Park Road Hampton Wl¢k Klngston Upon Tlwffl surrey r14A8 Date: ¥3..Fgbruary 2026 13 The Neurofibromatosis Assoclatlon Report and Financial Ststements Year Ended 31 October 2025 ststemont of Financial Activities {in¢ludlng Income & Expondlture Accounts) for the Year ended 31 October 2025 Tot•1 Totsl funds 2024 UDauoited 2025 202S 2025 Incomlng RMoUrC￿ from Gon￿￿ Funds Donations & Legxies Income from Charitable Activities Invo$lm•nt Incom• 118.353 472.658 402.954 52,123 26,902 1,730 53.653 28,902 71.183 13.314 Incomlng R•wJrc•• from Chwhabl• Actlvlti 4A329 120.013 655.411 487,431 Oth•r Incomlng Rowurc Total Incom• 4x329 120,013 $5SA11 487,431 Exp•ndltur• Cost of rai￿n0 fund8 Expenditur• on d)Ofrtablo 8Ctlvilies 133.788 133,788 114,890 300.695 113,528 414,221 370,998 Tot•1 R••aurc•• Exp•nd•d 44413 113,$26 S48,010 486,887 Mot Incom• (Expndlturn) 7N01 R•conGlll•llon of fund• Total funds brought forytsrd Net r￿Vement in funds lor year 826.491 22.128 848.618 847,073 6.556 7,401 Totsl fvnd• carrl•d lorvmnl 28,681 656,018 The 8tateThnt of fingna81 athl1￿ include8 all gainb k)B8e8 in the yew. Al incomirwj robtsur¢o8 snd r¢¥our¢•$ expended derive from conlinuing opwabons. 14 OU#5 The Neurofibromatosis Association Roport and Financial Statements Year Ended 31 October 2025 Balance shoot as at 31 Octobor 2025 2025 2024 Un8udrted T￿gible fixed assets io 1.320 2.284 Curr•nt a•e•ts Debtors Cash at bank al￿ in harKI 11 14.162 754,090 788.252 14.352 720.194 734.547 Creditors '. amounts f8lllng du• wrihin one y•ar 12 113.554 88,214 Net current a88•ts 664,698 646,333 Not ••¥•ts Ana￿￿• of r*t a••ets b•hw•n funds Unre8tricted fiJnd8 Restrtcted fur*d6 Total fund¥ 627.337 28.681 626.491 22.126 13 The trustees ackniAthdge their reaponsbilities for cOmpl￿'n9 thith the rewiremenis ofth• Conyanw kl 2006 wlh respect to accounting records and the preparth'on of accounts. Th• flnandal StsteM￿lS ar• prnpw•d in aco)rtarKe with the Spec￿ prov08￿8 of the Compani•s Act 20C6 and section 138 of Ihe Chants'es Act 2011. These accounts are prepargd in accordwi the Finoncial ROpo￿.n9 Standard applicable In the UK and RepublK of Ireland (FRS 1021 (effethe 1 January 2019) - (Charfttes SORP IFRS 102)). The note$ al pa9e$ 17 - 25 fcmi p*t of Ihese •xounts. Approv•d by the eoard olTr￿te￿ on 10 Febru￿ 2028, and ￿gned ts behaff by.. Rlchard Chalr of The Board of TnMt• & Company S•¢r•tsry Vlc• Ch•lr Company RegiStra￿n No. 03798407 Chartty Regi$tr¥tion No. 10787 Scothsh Charity Register No. SC045051 15 The Neurofibromatosis Assoclation Report and Flnanclal Ststsments Y•ar Endod 31 October 2025 Ststemwrt of for th• y•ar ond•d 31 Oct¢)bw 2025 2024 Unauditod Cash flows from owrnllng acVvltlè8 Ca¥h absorbed by (perai￿ 7.634 Net ¢ash ouffiow from op•raUng •cll¥lll•• 176,4781 Inv••tlng actfvitl•8 Purchase of tangljle fixed •*￿￿ Interest recelved N•t Infiow p.841) (4,569) 28,261 8.745 N•t Id•Grn•••ylnGr•u• In ¢••h & c••h •qul¥al•nl• 33,895 187,7341 C4sh & cash •qur¥alents at baginnlng of Perlod 720194 787 928 Ca•h & ca•h •qulv•l•nts at •nd of P•rlod 18 T¥pAou%S Th• Neurofibromatosis Association Report and Flnanclal Statements Year Ended 31 October 2025 Note8 to the Flnanclal Statements Accounllng polkle8 The prin￿PaI a¢¢oUnts￿￿ pol￿￿ are summarlged beknw. The acco￿ting wlK¥es have been applied ￿)nSIStenty throughout the year and tho we¢edwvJ y￿. The flnanc￿l statements conwty V•tth the Charttles A& 2011. the Companies Act 2006. Trustee Investm￿t IScotLandl Act 2005. the charities Aceounts (Scottand) Regulation$ 2006 la$ amended). the Memorandum and Articles of Assooatlon. aryl the Charitie¥ Statement of Recommended Practic• I'charltlss SORW} {8ppll¢•ble to ¢h8rille8 prtpariry th*r aceounta in a¢¢ord&nee WTth the Flnancial Reporting Stsndarrl applbcabb& ￿ the UK and Rewulc of Irelan¢Y." FRS 1021 effectlve from 1 January 2019. Tha Neurofftbroma￿ Aswgabon tr* dthillm ofa bonofft enyty urthr FRS 102. The finar￿al￿tatQnXfits arn kyepared kn 8tertlNJ. the funcaky￿I currency of tho Charty. Monetary amounts in these financial stknnents arn rounded to the nearnsl £. The fin8nGbg1 ¥tsten￿ts h•v• twn syepgred WKlerthe IM•kniral ¢onv•ntion. Th• yknci￿l •ccounllng unl•￿￿¢1￿ funds •r• av8il•t4• for #t th• ofth• tru81•￿ frJrthèranc8 of the general obAectsves of tho Charlty, and R8stncted fimds are s￿'ected to reslnction8 on eX￿l￿re Inwed by the donor. Incom• l incoming re8ourtss are included In the slatement of financial activltles wthen the tharity is ontsued to the income. and ts arr￿￿Trt Can b• quantified with r•asonabl• aceyr•¢y. Th¢ folbwlng •pecffjc policies a￿ applied to pawtwlar of inm.. Income frrrfn don*'ons arKI leg4ge¥ 13 rvKNeil by w ofwants. donaUonJ, fvndralsing aThJ gfftj and Is induded in ftrll In the Stat•nxnt of Financ181 Acts"V￿"ej when recelvable. Grants. wthere entthm¢nt 1$ not Condth￿al M tho dolivery of a Speclfic perfomsnce by the chgrity. arg rocognised vthen the tharity becomes uncorvjiiionally entitl￿ to the grant, The value of 8or¥iGes prowded by ¥o￿n￿er3 ha5 irKluded in tP*se acctsjnts, Income tr￿n charitable aclivilies are xcounted for when eamed. and Income resources from grants. Ithere Telated to Ferf0m￿nCe and d￿l￿rOble8, are accounted for th•nty e¥n$ the r&ht to consid•raVon by ttj pwlomianc•. d) Exwdltur• Expenditure Is recognlsed on an acxrual ba813 as a Kabllty Is Ir￿lTr8d. Expendmure Includes any VAT whtch cannot bg fvty Tecoverwd. aTrJ 1$ reprytgd a$ part of the expendibjre lo vthich il relates.. Costs of rai$in9 funds comprise the costs associated 7Mth attracting voluntary incomè. These indude those costs ass(￿￿ Mryih meeting the ¢onslitutional and ststulory requirements of ts charity aThJ strategic managemenl of Ihe chartty. Govemance costs comprise the costs assoGiated wth the goveman¢e of the charrty, indtsding audit fees, and a￿ shown separatety thin the Statement of Financial Act￿rt￿8 Expenditu￿ on ¢haritable aelivities compri￿ th0￿ costs incuffed by the chanty in the delNery of ris ac11vili￿ and Services fur its benefiu"ar*s. It indudes both ￿$ts that can b¢ alk)cated direw 10 acbvths and those costs of an indirect nature ne￿3Sary to 17 The NourofibromatO8is Assoclallon Report and Financial Statsments Year Endod 31 October 2025 All costs are allctated bet*Ren eX￿￿rt￿e categorie8 ofthe Ststemènt of FinaThio1 ACtiV￿"e9 on a bosis designed to refie¢t the use ofthe res￿ree. Depre(aabM." Assets aTe ￿Itten off ow ts4r* years on 8travJht hne bask8 of dwecth'on. Flxed Ag9•ts T8￿ble ￿ed assets are Inltlally measwed at cost and Wuenty measwed at cost or valuatk)n. of dekxeciation aThJ any impwmient losses. Indfvlrknl fixed a$￿ts cojlryi £250 or MO￿ cawtalisad ot Depreryation.. the value ofexh asset Is Mitten off over trKI years, M a ¥traW.Nne balis. Golng Goncem At the ￿m• of approvlng th• ffi￿n¢￿ statem￿. the Tnmtees have a r•asM•bl• exp￿t8￿0n that the Charty has adequate resour￿8 to continue in Op￿at￿￿al existe￿ for the fornseeable fijture. Thus. the Trusto•s conlinue to adopt thé goirvJ CA)ncom ba￿ of ￿&￿n11n9 in preparw th8 finaroal ststoments. g) D•btorn Tra¢Je and ottwr deL*m are rwiised at ••It1•￿ due. h) Crndltorn provl•bon• Cfedrtors and provSslon8 we recogni8¢d the ¢h*rty has a prnMnt obliga￿n re8uIUng from a pa81 èvent that will probabty r•sutt in Ihe tran8f•r of frJrKls to a third party and the amount due to Settle th• obllgaiaon can be meosured or estim*ed reh'abty. Creditors and rrfovlsitins are nom81ty re¢ogni$ed at th•ir 8etU•mont am(yJnL Infomi•tlon and l•g•l •tstu• of th• chMIty Nerve Tumours UK Is a Charltable Company, lknited by guarantee, incorporgted on 30 June 1999, and rtgistsred a8 8 charity on 6th Janu*y 2000 284853 regijtered 1982) with a membership ba8•. Th• ¢ompony w4$ •$tobli8h•d Ur￿*r ¥ M•m¢Jrandum of As8ooathJn. which estabkn'8had tho objects and powers of the charitable corrpany and Is goveirnd under its Articbej af Assockqbon. In the event of the company befing y￿und up rrthbers arn requirnd ty the adomed Const￿ to conlribute an amount not •xce8thrKJ £1. J) Pen8lon8 The penston costs charged In the fin8ne01 ststomwts rwe8ent the conlrfbLrtlon payat4e by the chA during the year. Contribut￿$ ore made to define(I ¢￿triL￿rtI￿ schemes m the UK. 18 The Neuroflbromatosls Assoclath)n Report and Flnancial Statements Yaar Endod 31 October 2025 Income Totsl fun(ts 2025 Total funds 2024 2025 202S Unaudiled al Donatlon• & Ltyacl•• DonaUon8 arKI glts Events Glft Ald Grants Logacitis Sub8CriPtion# 62.918 119,445 31.796 12.850 121.391 5,904 62,918 119.445 31.7 131,203 121.391 5.904 54,653 127,552 33,140 131,350 SO,231 8,028 118,353 3S4.303 118.353 472.658 402,954 bl Incom• from Chwltsbl• Acts¥ltl•• Fundraising 52,123 1.730 53,853 71,163 $2,123 1.730 53,863 71,163 ¢llrwMtm•nt In¢om• Inter•81 28,902 28.902 13,314 19 The Nourofibromatosls Assoclation Report and Flnanelal Statements Y￿r Ended 31 (ktober 2025 3. Grants Totsl funds 2024 nd8 2025 2025 2025 Unaudited Thè GTrce Tru81 The Peacock Tru¥t The G8rtleld Weston Foundatw The Three Oaks Trust The Nomian FomSty Ch***ble Tnmt Th• B$ron Davewt Cl￿rity The Schon Charitable Trust The Sir Jame8 Rollb Charilabi• Trust The Arolhlck Trust The Limbr￿k Hall Foundation Tho James Tudor Foundation The February Foundalknn A•xlon Pham￿¢0￿￿(•1s UK st Jude's Tru81 The Slr John & Lady Anx￿ Charllable Tnmt The Claire Mlln• Trust The Roger & Jt8n Jelcoate Trust Commlmity Lottery Fund Thè Cuthbert Hom Trust Th& Joseph Hopkln8 Chafliatjle Foundallon Th• Hadrian Tru8t The PF Edwards Charitsbh Tnmt The John Avins TnMI The Roger & Dou91•8 Tumer Trust Thè Thomas J Home Memryiol Trust The Grantham Yorke Trust The Sheffield TON￿ Tnbst The ￿c￿hall Charitable Trust The D'oyty Carte Charitable Tnmt Jeans 4 G8n•8 The Bunzl Famity Chantable Tnjst Thè BCH 1971 Charitable Tru¥t The ISED Foundation Tho StCrkV￿II Clffe TFUJt 1.500 8,000 20.000 10.000 20,000 10,000 10,000 1.000 2.000 500 1,500 1,500 150 8,000 5.000 15,OlX) 15.000 40,000 1.000 300 5.000 10,000 18.853 18.853 7,000 700 500 4.000 7,000 7,000 1,200 500 4,1)00 1,000 5,000 7th) 4,000 5.000 8.000 2,300 2,000 100 5,000 750 20,000 1,000 1,000 1000 20.000 12 20 Oup% Tho Neurofibromatosis A￿oCIation Report and Financial Statements Year Ended 31 October 2025 Expendituro &cikn NF Nurn T(rtal Co•t• dlw•ety •lh)¢•W ts>•*llwW•• 1￿￿d9ntAud1ty1 Fo• Fundrnhkng 35.133 40.9S2 198.758 198,758 NSA 108953 108 953 34 804 108 953 462,301 8ff ¢c4ts 1031 4A43 8304 .l(Kl 0,349 JO,035 14& 313 447 2.1ffi1 457 Pr•mh 22J8 15,851 3,301 28,011 1,152 Prfn1￿. and IT, taephoTh• aThJ fax 47 143 2.gS1 822 4,9 1.714 51.670 85 708 Total 2S0329 94804 119829 048010 •• •lkx4ted oixstsff ¢x4ts Fkn¥J8t Cc*ts It etc 21 Tho Nourofibromato8i8 Assoclatlon Report and Flnanclal Ststements Year Ended 31 October 2025 S. Not Incoming R•sourcgs for the Yoar TNS 1$ stste(l atsr charges.. 2025 2024 unaudited Depreciation Independent A￿jit Fee 3605 3042 2904 Staff c￿1* and nUffl￿rn 2024 2025 Unaudrted Sal#rieJ and wages Social security co8ts Pènslon costs 253,722 17,549 5,759 219,175 14,051 No employees received emolumnts of morv £80.000. ¢h•rty opwates a pn•lon #Ch￿ lor Its employees, as curmnty requlred. The avwage number of•mployee8 durfTrJ year. c*ulatsd (#) the of ful￿10M￿ equ1va1e￿ts. wa8 88 folknvA." %)25 2024 Unaudrfad CEO Membership Secrntary ITnnfomation Fundraising Spoclallsl Support Chgnge manager Development man8gern &r Tr￿1•• r•mun•r•ll¢)n No member¥ ofthe Boar(l of Tnmteu receNed wy reff￿neratIOn, or dwlng year. a8 tr previous financlal year. There ￿re no Related Party Transact¥)ns 4*Ying the y83r. No Trustee, er cther per8Cft re&tsd to tho charty, had any personal interest in any transxtion. Taxatlon As a ¢harTrty, The Neurofibrom*￿ A*s￿la￿ is exempt fr(xn tax on in¢tir￿ and gains falling within section SOS of the Taxe5 Act 1988 or s256 of1he Taxation of Ctwrgeable Gain5 Act 1992 to the extent thatthe8e are ￿pIled to its chafitabie oty"8cls. No tax Charges have arisen in Asscoalion. TUMOV The Nourofibromatosis Assoclallon Report and Flnancial Statements Y￿r Ended 31 Octob•r 2025 10. Tanglbl• fix•d 2025 2024 Ua#udilg0 Co•t AS at 1 November Add￿On# Removal of fvlty depreciated a$8ets As al 31 Oth>ber 16,205 2,841 11.636 4.589 ACC￿Tru1atsd d•prKlatlon As at 1 November Charge fof the year Removal offulty dO￿atsd a$set8 As 8131 October 13.921 3,605 10,879 3,042 13921 N•t book val A8 at 1 Novemtor A8 at 31 ¢3ctober 2284 757 11. Dobtorn 2025 2024 Unaudlle Debtor Control Rent Deposit Other debtors Prepayments 2,642 72 12. Cv•dltorn: am¢)un¢• falllng du• wlthln on• y 2025 2024 UngudilÉ Trade Creditors TaXa￿On Lottery Gr8nt Other Creditors A¢¢rual$ and deferred in¢ome 18.811 8.669 1 S,427 4.791 14.324 71.751 20,587 47,410 The Nourofibromatosis Association Report and Financial Statements Year Ended 31 October 2025 13. Analysis of not assets b•t%w•n lundi T¢)tal fund• fund fund• Tangible fixed assets Current assets Current l￿bilIti. 1.320 739,571 113.554 1.320 768,252 113.554 656 018 28.681 Unre$lricted reserves lotslling £627,337 have been carried forward, bLrt 80.4% of this figure, £503.870 is already designatfjd oxpfjnditure, due to the number of y￿r ¢(￿tracts *Mth NHS TrLbsts for tho Specialist NF Nurse posts, the head office rental ¢ontra¢t and other ¥pe¢ffic projects. This leaves a figure for free reserves of £123,486, for exPerKli￿r¢ in the next finaTr>•l year. Mov•m•nt In fund• At1 N¢wwnbw Incoming Outgolng 2024 RMour¢•• R••ourc At31 Octob•r 2025 R••trlct•d Fund• Support Gfoup*M•di¢al Info Days ResearchlSFrt￿l1st Support Nefv￿rk Awareness Campah3ns NF2 AcJvttle8 2,120 2,880 1,057 86,230 33,853 86.230 24.428 750 113.528 1,057 9,427 16,068 22,126 120.083 28,861 unr88tn.cted Funds 626,491 435.329 434.483 627,337 Total Fund• 648,617 555.411 548.010 6S6.018 PuTF*)ses of Restrfded Furth: Support GroUp￿med*al Inlo Days.. fvndkng restrlthd for eyTr*¢ure (n Medkal InfOrMa￿On Days ReseaTchlSSN'. nding restricted for expenditure on Re8earth NF2 activities.. fvnding restricknJ expendbture on NF2 activ Awarene8$ campaKJn￿Mfys'. fvrKling rnstncted for expenthlure on irrfom)ationlmeetings 15. Flnlndal commltments At 31 Odober 2025. the charty had annual commthents uThJer norpcancdlaljle werabThJ leases. followrs Tent renegot*atJons, as folkn￿. 2025 Explry datr: Not later than one year Later than one year a￿1 not later than fve ye 12,000 The Ngurofibromatosis Assocsation Report and Flnanclal Slatsments Year Ended 31 October 2025 16. Rgconciliation ol profft to ngt cash {outhow)finfi¢Jw fr¢xn ¢)pgrnting activitie¥ 2025 2024 Unaudited 8urplu¥llDoficlt} for th• y••r 7,401 Adju•tm8nl8 b) profft y••rb) r*t Cashftow from operath)g xllvlt1￿.' Depre¢ialion Flnanc8 Income 3,605 128.902) 3,042 (13.3141 Wortlng Capttol MI)￿Nn￿ {InGrOa￿)IdoGrea8e in debtors (8701 (66,8801 25,340 Cuh •b•orb•d by Ow•tl¢M 17. The preparallon olthe finandal statements requlw man•gem&rrt to mak• judg0￿rIts, •stim4tg8 arKI 488umptions that affect th8 amcmjnts rnport•d for as￿18 and Irabilrfies as at the balancg sheet dat8 and tho amounts reported for revenues arHI expen8es during the year. How*ver, the nature of estimatlon means that actual wt¢onx8 COU￿ diffw from th080 ¢stimate•. Thero *ro no key jWmonts. Tho main *£ountiry estimates are dew￿￿'on and xcruals. 25